1 July 2019 in Ophthalmology
30 March 2021 in British Journal of Ophthalmology
FAFrancisco Arnalich-Montiel
Francisco Arnalich-Montiel
+1
Aims We set out to identify risk factors for progression in untreated keratoconus patients from 34 centres across Australia, New Zealand, Spain and Italy. Methods Patients were divided into ‘progressors’ and ‘stable’ patients for each clinical parameter: visual acuity (VA), steepest keratometry (maximum keratometry (Max-K)) and thinnest corneal thickness (TCT). Primary outcomes were the proportion of eyes with sustained progression in VA, Max-K or TCT within 3 years. Secondary outcomes included predictors of progression. Results There were 3994 untreated eyes from 2283 patients. The proportion of eyes with VA, Max-K and TCT progression at 1 year were 3.2%, 6.6% and 3.1% respectively. Factors associated with VA loss were higher baseline VA (HR 1.15 per logMAR line increase in VA; p<0.001) and steeper baseline Max-K (HR 1.07 per 1D increase; p<0.001). Younger baseline age was associated with Max-K steepening (HR 0.96 per year older; p=0.001). Thicker baseline TCT, steeper baseline Max-K and younger baseline age were associated with TCT thinning: (HR 1.08 per 10 µm increase in TCT; p<0.001), (HR 1.03 per 1D increase; p=0.02) and (HR 0.98 per year younger; p=0.01), respectively. Conclusions Steeper Max-K and younger age were the most clinically useful baseline predictors of progression as they were associated with worsening of two clinical parameters. Every 1D steeper Max-K was associated with a 7% and 3% greater risk of worsening VA and thinning TCT, respectively. Each 1 year younger was associated with a 4% and 2% greater risk of steepening Max-K and thinning TCT, respectively.
24 October 2022 in Clinical & Experimental Ophthalmology
FAFrancisco Arnalich‐Montiel
Francisco Arnalich‐Montiel
+1
Background: We aimed to determine the long‐term outcomes of epithelium‐off cross‐linking (CXL) in keratoconus patients.Methods: An observational registry study from 41 centres across 5 countries was carried out. Primary outcomes included the mean change in visual acuity (VA), Kmax, K2, and thinnest corneal thickness (TCT) at 1–5 years. Secondary outcomes included the percentage of eyes with worsening, stable and improving outcomes.Results: There were 976 eyes of 794 patients with 1‐year of complete follow‐up, 501 eyes with 2‐years, 355 with 3‐years, 235 with 4‐years and 162 with 5‐years. There was a significant improvement in mean VA from baseline by 3.7 logMAR letters (p < 0.001) in year 1, and 6.9 (p < 0.001) in year 5. Mean Kmax decreased by 1.2 dioptres (D;p < 0.01) in year 1. During subsequent years the Kmax flattening appeared sustained but this was not statistically significant. K2 flattened significantly from baseline in year 1 and then remained stable. At 1 year, 4.1% patients were poor responders to CXL in terms of VA, losing ≥15 letters. The proportion of the poor responders remained unchanged: 4.9% at 5‐years. The proportion of poor responders in terms of Kmax remained similar: 5.9% steepening by ≥2D at 1‐year and 7.5% at 5‐years. The proportion of K2 poor responders remained stable with 4.7% steepening by ≥2D at 1‐year and 5.8% at 5‐years.Conclusions: Cross‐linking is effective at stabilising keratoconus up to 5 years in most patients. However, a small proportion of eyes failed to stabilise and had reduced vision.